Radiation oncology firm Accuray posted relatively flat results for its fiscal fourth quarter and year-end revenues for 2015.
For the quarter (end-June 30), the company's revenues were $101.8 million, compared with $102 million for the same period last year. Its total 2015 revenues were $379.8 million, 3% higher than 2014's $369.4 million.
The company's fourth-quarter net losses decreased slightly, from $9.8 million in 2014 to $5.6 million. For the year, however, its net loss increased, from $35.4 million to $40.2 million.
The company expects fiscal 2016 revenue to be in the range of $395 million to $410 million, a growth of 4% to 8% over fiscal 2015.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
